Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.37 |
| ▸ | ADCY2 | Q08462 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | MAOB | P27338 | 3/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18011887 | 0.96 | MAPK1 (0.44) | MAPK1LMNAMAPTSMN1; SMN2MEN1 | |
| SCHEMBL19795853 | 0.88 | MDM2 (0.38) | LMNAMEN1KMT2A | |
| SCHEMBL19795858 | 0.88 | LMNA (0.34) | LMNAMAPTSMN1; SMN2MEN1KMT2A | |
| SCHEMBL19795842 | 0.85 | ALDH1A1 (0.34) | LMNASMN1; SMN2MEN1KMT2ACYP19A1 | |
| SCHEMBL19795855 | 0.84 | LMNA (0.35) | LMNAMAPTMEN1KMT2A | |
| SCHEMBL18012011 | 0.83 | CYP19A1 (0.43) | LMNAMAPTSMN1; SMN2MEN1KMT2A | |
| SCHEMBL19795850 | 0.82 | CYP19A1 (0.40) | LMNAMAPTSMN1; SMN2MEN1KMT2A | |
| SCHEMBL18012015 | 0.82 | STING1 (0.35) | MAPK1LMNAMAPTSMN1; SMN2MEN1 | |
| SCHEMBL18011890 | 0.82 | MDM2 (0.38) | MEN1KMT2A | |
| SCHEMBL737972 | 0.81 | TP53 (0.41) | LMNASMN1; SMN2MEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180022697-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS AND THERAPEUTIC METHODS USING THE SAME | UNIV MICHIGAN REGENTS (US) | 2018-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180022697-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS AND THERAPEUTIC METHODS USING THE SAME | GBA1, GBA2, GAA | MAPK1 4023/4885LMNA 1219/4885MAPT 1916/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.